Post-Approved Phase III Study of 1-LV/5FU Therapy
Phase 3
20 Years
77 Years
20 Years
77 Years
Not Enrolling
Both
Gastric Cancer
Both
Gastric Cancer
Trial Information
Post-Approved Phase III Study of 1-LV/5FU Therapy
Inclusion Criteria:
- Gastric cancer diagnosed histologically or cytologically
- Normal organ function of bone marrow, heart, liver and kidney
- Age of 20-77
Other inclusion applies
Exclusion Criteria:
- Serious infection, heart disease, complication or organ disorder
- Ongoing administration of flucytosine
- Pregnant or breastfeeding women
Other exclusion applies
Type of Study:
Interventional
Study Design:
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Survival time
Principal Investigator
Medical Monitor
Investigator Role:
Study Director
Investigator Affiliation:
Wyeth is now a wholly owned subsidiary of Pfizer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
ISO/5FU-10
NCT ID:
NCT00195572
Start Date:
May 2002
Completion Date:
August 2008
Related Keywords:
- Gastric Cancer
- Gastric Cancer
- Advanced/Recurrent Gastric Cancer
- Stomach Neoplasms
Name | Location |
|---|
